Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities.

Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS.

Front Oncol. 2019 Feb 4;9:41. doi: 10.3389/fonc.2019.00041. eCollection 2019. Review.

2.

Spatiotemporal Evolution of the Primary Glioblastoma Genome.

Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, Nam SH, Kim BS, Johnson MD, Kong DS, Seol HJ, Lee JI, Joo KM, Yoon Y, Park WY, Lee J, Park PJ, Nam DH.

Cancer Cell. 2015 Sep 14;28(3):318-28. doi: 10.1016/j.ccell.2015.07.013.

3.

20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.

Chen Z, Wei X, Shen L, Zhu H, Zheng X.

Cancer Sci. 2019 Jan;110(1):389-400. doi: 10.1111/cas.13881. Epub 2018 Dec 14.

4.

Gene expression profiling predicts response to temozolomide in malignant gliomas.

Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E, Tsumoto K.

Int J Oncol. 2010 Jun;36(6):1367-77.

PMID:
20428759
5.

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, Malmström A, Hallbeck M, Heimans JJ, Kloezeman JJ, Stenmark-Askmalm M, Lamfers ML, Saito N, Aburatani H, Mukasa A, Berger MS, Söderkvist P, Taylor BS, Molinaro AM, Wesseling P, Reijneveld JC, Chang SM, Ylstra B, Costello JF.

Acta Neuropathol. 2015 Apr;129(4):597-607. doi: 10.1007/s00401-015-1403-6. Epub 2015 Feb 28.

6.

The strategy for enhancing temozolomide against malignant glioma.

Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J.

Front Oncol. 2012 Aug 14;2:98. doi: 10.3389/fonc.2012.00098. eCollection 2012.

7.

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M.

J Neurochem. 2006 Feb;96(3):766-76. Epub 2006 Jan 9.

8.

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M.

Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421. doi: 10.2176/nmc.ra.2018-0141. Epub 2018 Sep 21. Review.

9.

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.

Chong DQ, Toh XY, Ho IA, Sia KC, Newman JP, Yulyana Y, Ng WH, Lai SH, Ho MM, Dinesh N, Tham CK, Lam PY.

BMC Cancer. 2015 Apr 11;15:255. doi: 10.1186/s12885-015-1191-3.

10.

Effect of IFN-beta on human glioma cell lines with temozolomide resistance.

Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E.

Int J Oncol. 2009 Jul;35(1):139-48.

PMID:
19513561
11.

Impact of temozolomide on immune response during malignant glioma chemotherapy.

Sengupta S, Marrinan J, Frishman C, Sampath P.

Clin Dev Immunol. 2012;2012:831090. doi: 10.1155/2012/831090. Epub 2012 Oct 24. Review.

12.

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.

Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15.

PMID:
26188279
13.

Temozolomide-associated hypermutation in gliomas.

Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF.

Neuro Oncol. 2018 Sep 3;20(10):1300-1309. doi: 10.1093/neuonc/noy016.

14.

O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.

Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L.

Int J Mol Sci. 2012;13(6):6983-94. doi: 10.3390/ijms13066983. Epub 2012 Jun 7.

15.

β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.

Bi Y, Li H, Yi D, Bai Y, Zhong S, Liu Q, Chen Y, Zhao G.

Cancer Lett. 2018 Oct 28;435:66-79. doi: 10.1016/j.canlet.2018.07.040. Epub 2018 Aug 4.

PMID:
30081068
16.

Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.

Pan Q, Yang XJ, Wang HM, Dong XT, Wang W, Li Y, Li JM.

Cell Biochem Biophys. 2012 Jan;62(1):185-91. doi: 10.1007/s12013-011-9280-7.

PMID:
21892781
17.

Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.

Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, Zhang J, Lan Q, Huang Q.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2079-84. doi: 10.1007/s00432-012-1290-3. Epub 2012 Jul 24.

PMID:
22825126
18.

Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.

Chamberlain MC.

Expert Rev Neurother. 2010 Oct;10(10):1537-44. doi: 10.1586/ern.10.32. Review.

PMID:
20925470
19.

Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.

Fukushima T, Takeshima H, Kataoka H.

Anticancer Res. 2009 Nov;29(11):4845-54. Review.

20.

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.

Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF.

J Clin Oncol. 2010 Apr 20;28(12):2051-7. doi: 10.1200/JCO.2009.26.5520. Epub 2010 Mar 22. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

PMID:
20308655

Supplemental Content

Support Center